Spots Global Cancer Trial Database for In-Vivo Activated T-Cell Depletion to Prevent GVHD
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: In-Vivo Activated T-Cell Depletion to Prevent GVHD
Official Title: In-Vivo Activated T-Cell Depletion to Prevent GVHD
Study ID: NCT00594308
Study Description
Brief Summary: The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine with cyclosporine alone for the prevention of graft-versus-host disease. This research is being done because there is no completely safe and effective prevention for graft-versus-host disease. It is known that cyclosporine helps with GVHD but we would like to know if the addition of basiliximab will decrease the incidence and/or severity of GVHD after a transplant known as nonmyeloablative ("mini" transplant).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Indiana Universtiy Simon Cancer Center, Indianapolis, Indiana, United States
Contact Details
Name: Robert Nelson, MD
Affiliation: Indiana Universtiy School of Medicine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
